Circulating cell-free DNA and its association with cardiovascular disease: What we know and future perspectives
Research output: Contribution to journal › Review › Research › peer-review
Standard
Circulating cell-free DNA and its association with cardiovascular disease : What we know and future perspectives. / Thorsen, Steffen Ullitz; Moseholm, Kristine Frøsig; Clausen, Frederik Banch.
In: Current Opinion in Lipidology, Vol. 35, No. 1, 2024, p. 14-19.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Circulating cell-free DNA and its association with cardiovascular disease
T2 - What we know and future perspectives
AU - Thorsen, Steffen Ullitz
AU - Moseholm, Kristine Frøsig
AU - Clausen, Frederik Banch
N1 - Publisher Copyright: © 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Purpose of reviewThe aim of this review is to explore a possible link between cell-free DNA (cfDNA) and cardiovascular disease (CVD), which may hold valuable potential for future diagnostics.Recent findingscfDNA has become topic of high interest across several medical fields. cfDNA is used as a diagnostic biomarker in cancer, prenatal care, and transplantation. In addition, cfDNA may play an unrecognized role in biological processes that are involved in or underlying various disease states, for example, inflammation. Elevated levels of cfDNA are associated with various elements of CVD, cardio-metabolic risk factors, and autoimmune diseases. Mitochondrial cfDNA and neutrophil extracellular traps may play distinct roles. Total circulating cfDNA may reflect the unspecific accumulation of stressors and the organism's susceptibility and resilience to such stressors. As such, cfDNA, in a stressful situation, may provide predictive value for future development of CVD. We suggest exploring such possibility through a large-scale prospective cohort study of pregnant women.SummaryThere is no doubt that cfDNA is a valuable biomarker. For CVD, its potential is indicated but less explored. New studies may identify cfDNA as a valuable circulating cardiovascular risk marker to help improve risk stratification.
AB - Purpose of reviewThe aim of this review is to explore a possible link between cell-free DNA (cfDNA) and cardiovascular disease (CVD), which may hold valuable potential for future diagnostics.Recent findingscfDNA has become topic of high interest across several medical fields. cfDNA is used as a diagnostic biomarker in cancer, prenatal care, and transplantation. In addition, cfDNA may play an unrecognized role in biological processes that are involved in or underlying various disease states, for example, inflammation. Elevated levels of cfDNA are associated with various elements of CVD, cardio-metabolic risk factors, and autoimmune diseases. Mitochondrial cfDNA and neutrophil extracellular traps may play distinct roles. Total circulating cfDNA may reflect the unspecific accumulation of stressors and the organism's susceptibility and resilience to such stressors. As such, cfDNA, in a stressful situation, may provide predictive value for future development of CVD. We suggest exploring such possibility through a large-scale prospective cohort study of pregnant women.SummaryThere is no doubt that cfDNA is a valuable biomarker. For CVD, its potential is indicated but less explored. New studies may identify cfDNA as a valuable circulating cardiovascular risk marker to help improve risk stratification.
KW - cardiovascular diseases
KW - cell-free nucleic acids
KW - epidemiology
KW - immunology
KW - inflammation
U2 - 10.1097/MOL.0000000000000907
DO - 10.1097/MOL.0000000000000907
M3 - Review
C2 - 37800671
AN - SCOPUS:85180320419
VL - 35
SP - 14
EP - 19
JO - Current Opinion in Lipidology
JF - Current Opinion in Lipidology
SN - 0957-9672
IS - 1
ER -
ID: 382331895